---
document_datetime: 2025-11-06 14:20:18
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lenalidomide-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lenalidomide-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.8394973
conversion_datetime: 2025-12-17 07:48:06.650258
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Lenalidomide Mylan

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | Notification acc.Article61(3)-Accepted | 06/11/2025                          |                                          | PL                              |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000309298                      | Update of the package leaflet with revised contact details oflocal representatives. Additionally,theMAH tooktheopportunity toaddthelatestrenewalCommission Decisioninsection9oftheSmPC.                                                                                                                          |            |            |                 |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| Variation type IB / EMA/VR/0000268655 | Thiswas an applicationfor avariation following a worksharing procedure according toArticle 20 of CommissionRegulation(EC) No 1234/2008. B.1I.e)Container closure system-B.II.e.z Othervariation-Accepted                                                                                                         | 10/07/2025 | N/A        |                 |
| Renewal -5year/ EMA/R/0000257483      | -Renewal-Accepted Renewal of marketing authorisation.                                                                                                                                                                                                                                                            | 19/06/2025 | 21/08/2025 | SmPC            |
| Variation typeIA/ EMA/VR/0000256112   | A.ADMINISTRATIVECHANGES-A.7 Deletion of manufacturingsitesfor an active substance,intermediate orfinishedproduct, packaging site,manufacturerresponsiblefor batchrelease,sitewherebatchcontrol takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted | 03/03/2025 | N/A        | Annex II and PL |
| Variation type IA / EMA/VR/0000245155 | This was an application for a group of variations.                                                                                                                                                                                                                                                               | 27/01/2025 | N/A        |                 |

<div style=\"page-break-after: always\"></div>

B.III.1.bEuropeanPharmacopoeial TSE Certificate ofsuitabilityfor an active substance/startingmaterial/reagent/ intermediate/or excipient - B.III.1.b.3 Updated certificate from an already approved manufacturer-Accepted

B.IIl.1.bEuropeanPharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/orexcipient-B.Ill.1.b.3 Updated certificate from an already approved manufacturer-Accepted

B.III.1.bEuropeanPharmacopoeialTSE Certificate ofsuitabilityfor an active substance/startingmaterial/reagent/ intermediate/or excipient -B.II1.1.b.2 New certificateforastartingmaterial/reagent/ intermediate/orexcipientfromanewor an alreadyapprovedmanufacturer-Accepted